| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JCPH.410 |
| P698 | PubMed publication ID | 25302940 |
| P2093 | author name string | Hua Liu | |
| Diane R Mould | |||
| Xiaofei Zhou | |||
| Ashley Milton | |||
| Jeffrey Ecsedy | |||
| Karthik Venkatakrishnan | |||
| Hadi Danaee | |||
| Howard Fingert | |||
| Robert Kleinfield | |||
| P2860 | cites work | Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells | Q40009243 |
| Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. | Q40118820 | ||
| Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors | Q40322284 | ||
| Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase | Q40416068 | ||
| Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase | Q42481060 | ||
| Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations | Q42509176 | ||
| Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237). | Q46938025 | ||
| Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. | Q52644048 | ||
| Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. | Q53159452 | ||
| Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics | Q24651239 | ||
| Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells | Q28206475 | ||
| A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers | Q28272347 | ||
| Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? | Q33296440 | ||
| Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma | Q33402188 | ||
| Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q33412196 | ||
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma | Q33944281 | ||
| Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts | Q34301953 | ||
| Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. | Q34464172 | ||
| Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study | Q34498390 | ||
| Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. | Q34529891 | ||
| Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression | Q34995467 | ||
| Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. | Q35549470 | ||
| Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes | Q36102590 | ||
| Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer | Q36904564 | ||
| Aurora-A: the maker and breaker of spindle poles | Q36917445 | ||
| Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. | Q36980076 | ||
| Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia | Q37269040 | ||
| Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection | Q37288945 | ||
| Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. | Q37327280 | ||
| Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs | Q37581236 | ||
| Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development | Q37962099 | ||
| Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays | Q39455013 | ||
| Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells | Q39506267 | ||
| MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo | Q39733225 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 336-347 | |
| P577 | publication date | 2014-10-09 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships | |
| P478 | volume | 55 |
| Q57812608 | Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial |
| Q51752158 | Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. |
| Q48157676 | Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. |
| Q38996431 | Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science |
| Q47156672 | Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. |
| Q58607198 | Mass balance, routes of excretion, and pharmacokinetics of investigational oral [C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors |
| Q38865758 | Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors |
| Q90739914 | Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies |
| Q55056081 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. |
| Q26784060 | Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer |
| Q38756932 | The Aurora kinase inhibitors in cancer research and therapy |
| Q38719689 | Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
Search more.